Analysis of the relationship between body composition and the pharmacokinetics of panitumumab in the treatment of localized squamous cell carcinoma of the anus – An ancillary study of the FFCD0904 phase I and II trial

This exploratory analysis suggests that BW and BC may influence panitumumab PK, with patients who had lower BW, FM and FFM might have reduced exposure and clearance. Interpretation should be cautious due to the small sample size, confounding effect between BC and BW and potential disease-related effects. Larger studies with longitudinal BC and PK assessments are needed to clarify these relationships and guide dosing strategies.